SELLAS Life Sciences (SLS) Change in Accured Expenses (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Change in Accured Expenses of -$1.3 million for Q1 2026, up 56.34% year-over-year from -$808502.0 in Q1 2025, and down 331.93% quarter-over-quarter from $545000.0 in Q4 2025.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Change in Accured Expenses for 17 consecutive years, with -$1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 56.34% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at -$310000.0 (up 92.32% YoY), while the FY2025 annual figure was -$1.9 million, up 11.13% from the prior year.
- Change in Accured Expenses eased to -$1.3 million in Q1 2026 per SLS's latest filing, from $545000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.7 million in Q4 2022 and bottomed at -$2.9 million in Q1 2025.
- Historically, Change in Accured Expenses has averaged -$17294.1 across 5 years, with a median of $196000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 2713.11% — and 2024, when it tumbled 631.63%.
- SELLAS Life Sciences' Change in Accured Expenses stood at $1.7 million in 2022, then slumped by 53.03% to $806000.0 in 2023, then plunged by 102.98% to -$24000.0 in 2024, then soared by 2370.83% to $545000.0 in 2025, then plunged by 331.93% to -$1.3 million in 2026.
- Business Quant data shows SLS's Change in Accured Expenses at -$1.3 million in Q1 2026, $545000.0 in Q4 2025, and $897000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 68.82 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | 1.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Mn |
| Mar 31, 2026 | -1.26 Mn |
| Dec 31, 2025 | 545,000.00 |
| Sep 30, 2025 | 897,000.00 |
| Jun 30, 2025 | -488,000.00 |
| Mar 31, 2025 | -2.90 Mn |
| Dec 31, 2024 | -24,000.00 |
| Sep 30, 2024 | 307,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | 806,000.00 |
| Sep 30, 2023 | 689,000.00 |
| Jun 30, 2023 | -242,000.00 |
| Mar 31, 2023 | 196,000.00 |
| Dec 31, 2022 | 1.72 Mn |
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 215,000.00 |
| Mar 31, 2022 | 151,000.00 |
| Dec 31, 2021 | 61,000.00 |
| Sep 30, 2021 | 802,000.00 |